Kristin M Andruska, MD
Neurology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Andruska’s office at (650) 484-0440 to ask if they take your plan before you enroll.
California Medical Board record
Licence A136541 · Current
Licensed to practise in California · since 2015 · expires 2027-02-28 · University of Minnesota Medical School.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$32,513
Medicare paid this office $32,513 for 36 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 35 | $16,269 | $158 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 32 | $6,516 | $29 |
Who their Medicare patients are
36 Original Medicare patients in 2024. Average age 75 · Also on Medicaid 0% · Health risk score 1.41. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 53%.
The office billed $60,020, Medicare allowed $43,074 and paid $32,513; for 1,479 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 36 | 1,479 | 75 | 1.41 | $60,020 | $32,513 |
| 2023 | 37 | 1,764 | 75 | 1.34 | $60,365 | $34,062 |
| 2022 | 39 | 3,296 | 76 | 1.27 | $69,322 | $39,777 |
| 2021 | 34 | 4,347 | 74 | 1.34 | $87,825 | $51,799 |
| 2020 | 166 | 4,740 | 75 | 1.41 | $127,474 | $63,937 |
| 2019 | 150 | 5,263 | 75 | 1.44 | $176,142 | $85,002 |
| 2018 | 65 | 143 | 76 | 1.86 | $37,639 | $17,852 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 36 | $15,822 | $161 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 37 | $5,955 | $29 |
2022: 2 services
| Long return visit (40+ min) | 37 | $15,101 | $159 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 29 | $3,747 | $30 |
2021: 2 services
| Long return visit (40+ min) | 34 | $16,341 | $178 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 31 | $3,738 | $31 |
2020: 8 services
| Botox | 13 | $16,501 | None |
| Long return visit (40+ min) | 102 | $16,067 | $117 |
| Return visit (30+ min) | 75 | $8,214 | $94 |
| Injection, rimabotulinumtoxinb, 100 units | 12 | $7,095 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 16 | $1,787 | $99 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 30 | $1,559 | $35 |
| Exam of neurobehavioral status, first hour | 14 | $1,277 | $91 |
| Short return visit (20+ min) | 12 | $916 | $70 |
2019: 7 services
| Long return visit (40+ min) | 125 | $36,961 | $129 |
| Botox | 12 | $21,129 | None |
| Return visit (30+ min) | 54 | $5,481 | $86 |
| New patient visit (60+ min) | 15 | $2,430 | $162 |
| Extended office or other outpatient service, first hour | 15 | $2,237 | $118 |
| Short return visit (20+ min) | 19 | $2,189 | $68 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 14 | $944 | $34 |
2018: 4 services
| Long return visit (40+ min) | 53 | $9,942 | $124 |
| Extended office or other outpatient service, first hour | 32 | $3,947 | $116 |
| New patient visit (60+ min) | 12 | $2,297 | $191 |
| Return visit (30+ min) | 12 | $1,224 | $102 |
Drugs they prescribed that Part D paid
$67,244
Pharmacies billed $67,244 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 295) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
246 generic and 49 brand-name prescriptions · $67,244 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 28 | $22,454 | $802 |
| Rasagiline Mesylate | None | 48 | $11,272 | $235 |
| Carbidopa-Levodopa | None | 76 | $3,752 | $49 |
| Carbidopa-Levodopa Er | None | 23 | $1,443 | $63 |
| Midodrine | None | 15 | $1,114 | $74 |
See all 8 drugs
| Rytary | Parkinson's | 28 | $22,454 | $802 |
| Rasagiline Mesylate | None | 48 | $11,272 | $235 |
| Carbidopa-Levodopa | None | 76 | $3,752 | $49 |
| Carbidopa-Levodopa Er | None | 23 | $1,443 | $63 |
| Midodrine | None | 15 | $1,114 | $74 |
| Amantadine | None | 12 | $910 | $76 |
| Donepezil | None | 29 | $556 | $19 |
| Escitalopram | None | 14 | $274 | $20 |
Year by year
| 2024 | 295 | 33 | 0% (0) | 17% | $67,244 |
| 2023 | 254 | 34 | 0% (0) | 17% | $128,942 |
| 2022 | 322 | 32 | 0% (0) | 24% | $193,886 |
| 2021 | 423 | 62 | 0% (0) | 23% | $249,011 |
| 2020 | 1,167 | 156 | 0% (0) | 23% | $597,417 |
| 2019 | 1,101 | 119 | 0% (0) | 26% | $793,367 |
| 2018 | 257 | 36 | 0% (0) | 31% | $91,954 |
| 2016 | 28 | 11 | 0% (0) | None | $4,626 |
| 2015 | 144 | 18 | 0% (0) | 15% | $32,061 |
| 2014 | 65 | None | 0% (0) | 0% | $4,403 |
| 2013 | 54 | 13 | 0% (0) | None | $3,201 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Rasagiline Mesylate | None | 46 | $23,040 | $501 |
| Rytary | Parkinson's | 16 | $14,338 | $896 |
| Carbidopa-Levodopa | None | 64 | $3,953 | $62 |
| Midodrine | None | 13 | $1,367 | $105 |
| Donepezil | None | 31 | $1,076 | $35 |
| Memantine | None | 11 | $1,017 | $92 |
| Escitalopram | None | 12 | $606 | $51 |
| Amantadine | None | 11 | $583 | $53 |
2022: 9 drugs
| Nuplazid | Parkinson's psychosis | 24 | $111,681 | $4,653 |
| Rasagiline Mesylate | None | 50 | $26,345 | $527 |
| Rytary | Parkinson's | 27 | $22,480 | $833 |
| Carbidopa-Levodopa | None | 73 | $6,566 | $90 |
| Entacapone | None | 12 | $3,919 | $327 |
| Carbidopa-Levodopa Er | None | 26 | $3,647 | $140 |
| Midodrine | None | 14 | $2,164 | $155 |
| Donepezil | None | 17 | $747 | $44 |
| Escitalopram | None | 11 | $381 | $35 |
2021: 12 drugs
| Nuplazid | Parkinson's psychosis | 23 | $109,832 | $4,775 |
| Rytary | Parkinson's | 46 | $54,583 | $1,187 |
| Rasagiline Mesylate | None | 57 | $25,908 | $455 |
| Inbrija | None | 13 | $13,781 | $1,060 |
| Carbidopa-Levodopa | None | 93 | $8,157 | $88 |
| Entacapone | None | 11 | $4,083 | $371 |
| Rivastigmine | None | 13 | $3,700 | $285 |
| Midodrine | None | 13 | $2,124 | $163 |
| Carbidopa-Levodopa Er | None | 28 | $2,039 | $73 |
| Amantadine | None | 16 | $749 | $47 |
| Donepezil | None | 24 | $481 | $20 |
| Escitalopram | None | 13 | $334 | $26 |
2020: 25 drugs
| Rytary | Parkinson's | 118 | $155,885 | $1,321 |
| Rasagiline Mesylate | None | 93 | $63,016 | $678 |
| Inbrija | None | 23 | $50,868 | $2,212 |
| Nuplazid | Parkinson's psychosis | 11 | $46,818 | $4,256 |
| Carbidopa-Levodopa | None | 248 | $20,451 | $82 |
| Neupro | None | 15 | $15,951 | $1,063 |
| Myrbetriq | None | 12 | $13,624 | $1,135 |
| Carbidopa-Levodopa-Entacapone | None | 19 | $12,285 | $647 |
| Xadago | None | 11 | $10,356 | $941 |
| Pramipexole Er | None | 12 | $10,022 | $835 |
| Carbidopa-Levodopa Er | None | 86 | $9,035 | $105 |
| Entacapone | None | 13 | $7,423 | $571 |
| Amantadine | None | 49 | $5,601 | $114 |
| Rivastigmine | None | 23 | $4,638 | $202 |
| Ropinirole Er | None | 17 | $3,575 | $210 |
| Midodrine | None | 35 | $2,894 | $83 |
| Memantine | None | 11 | $1,915 | $174 |
| Donepezil | None | 53 | $1,386 | $26 |
| Pramipexole Dihydrochloride | None | 16 | $1,284 | $80 |
| Fludrocortisone Acetate | None | 11 | $1,163 | $106 |
| Clozapine | None | 17 | $675 | $40 |
| Duloxetine | None | 11 | $468 | $43 |
| Escitalopram | None | 40 | $467 | $12 |
| Clonazepam | None | 33 | $256 | $8 |
| Citalopram Hbr | None | 16 | $167 | $10 |
2019: 25 drugs
| Northera | None | 20 | $371,332 | $18,567 |
| Rytary | Parkinson's | 99 | $127,800 | $1,291 |
| Nuplazid | Parkinson's psychosis | 24 | $76,050 | $3,169 |
| Rasagiline Mesylate | None | 80 | $62,661 | $783 |
| Xadago | None | 19 | $20,147 | $1,060 |
| Carbidopa-Levodopa | None | 261 | $16,983 | $65 |
| Pramipexole Er | None | 19 | $13,749 | $724 |
| Neupro | None | 19 | $12,894 | $679 |
| Carbidopa-Levodopa-Entacapone | None | 23 | $9,828 | $427 |
| Rivastigmine | None | 30 | $9,234 | $308 |
| Amantadine | None | 46 | $5,625 | $122 |
| Entacapone | None | 12 | $5,453 | $454 |
| Carbidopa-Levodopa Er | None | 68 | $4,905 | $72 |
| Midodrine | None | 44 | $4,050 | $92 |
| Selegiline | None | 21 | $936 | $45 |
| Escitalopram | None | 29 | $885 | $31 |
| Clozapine | None | 24 | $718 | $30 |
| Gabapentin | None | 17 | $511 | $30 |
| Duloxetine | None | 11 | $401 | $36 |
| Clonazepam | None | 37 | $392 | $11 |
| Buspirone | None | 17 | $372 | $22 |
| Mirtazapine | None | 12 | $311 | $26 |
| Donepezil | None | 16 | $230 | $14 |
| Lorazepam | None | 18 | $187 | $10 |
| Citalopram Hbr | None | 17 | $164 | $10 |
2018: 5 drugs
| Nuplazid | Parkinson's psychosis | 14 | $39,225 | $2,802 |
| Rytary | Parkinson's | 53 | $26,317 | $497 |
| Carbidopa-Levodopa | None | 70 | $4,955 | $71 |
| Rivastigmine | None | 14 | $1,871 | $134 |
| Carbidopa-Levodopa Er | None | 22 | $733 | $33 |
2015: 4 drugs
| Entacapone | 15 | $6,670 | $445 |
| Carbidopa-Levodopa | 28 | $1,856 | $66 |
| Levetiracetam | 25 | $472 | $19 |
| Topiramate | 24 | $291 | $12 |
2014: 3 drugs
| Gabapentin | 13 | $1,091 | $84 |
| Nortriptyline | 11 | $149 | $14 |
| Amitriptyline | 11 | $126 | $11 |
2013: 1 drug
| Amitriptyline | 15 | $59 | $4 |
Money from drug and device companies
$62 in 2024
| 2024 | 1 | 1 | None | $62 |
| 2023 | 3 | 4 | None | $257 |
| 2022 | 1 | 5 | None | $202 |
| 2021 | 2 | 4 | None | $133 |
| 2020 | 4 | 7 | None | $343 |
| 2019 | 7 | 16 | $18 | $1,260 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | None | $62 | 1 payment
|
See the published payment
| Boston Scientific | Meals · 2024-06-06 | None | $62 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $257
| Medtronic | Percept PC Brainsense | $177 | 2 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $56 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $24 | 1 payment
|
2022: $202
| Boston Scientific | General - Dbs | $202 | 5 payments
|
2021: $133
| Boston Scientific | General Dbs | $105 | 3 payments
|
| Medtronic | Percept | $28 | 1 payment
|
2020: $343
| Medtronic USA | Activa | $134 | 3 payments
|
| Boston Scientific | General - Dbs | $127 | 2 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $61 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $22 | 1 payment
|
2019: $1,260
| Boston Scientific | General Dbs | $717 | 7 payments
|
| Medtronic USA | Activa | $437 | 3 payments
|
| AbbVie | Duopa | $25 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $23 | 1 payment
|
| Ucb | Neupro | $21 | 1 payment
|
| US WorldMeds | Xadago | $19 | 1 payment
|
| Acorda Therapeutics | Inbrija | $18 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| GENZYME CORPORATION · Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Gz/Sar402671 in Patients With Early-Stage Parkinson'S Disease · 2019 | Their institution | $110,166 |
| GENZYME CORPORATION · Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Gz/Sar402671 in Patients With Early-Stage Parkinson''S Disease Carrying A Gba Mutation Or Other Pre-Specified Variant · 2020 | Their institution | $62,285 |
| GENZYME CORPORATION · Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Gz/Sar402671 in Patients With Early-Stage Parkinson'S Disease Carrying A Gba Mutation Or Other Pre-Specified Variant. · 2021 | Their institution | $4,285 |
Professional record
- NPI
- 1619263431
- Licence
- CA 136541California A136541: Current · expires 2027-02-28
- Trained
- University of Minnesota Medical School, 2011
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- Po Box 391344, Mountain View, CA, 94039
- NPI first listed
- 2011-06-20
- NPI last updated
- 2020-10-08
- NPI record certified
- 2020-10-08
This is when the NPI record was last certified, not a medical board exam.